Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT ID: NCT03556098
Last Updated: 2021-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2019-02-22
2020-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes
NCT01414556
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
NCT00603031
Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?
NCT01048268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIP
Infusion of Glucose-dependent insulinotropic peptide
glucose-dependent insulinotropic peptide
Infusion of GIP
GIP[3-30]
Infusion of GIP\[3-30\]
Glucose-Dependent Insulin-Releasing Hormone[3-30]
Infusion of GIP antagonist GIP\[3-30\]
Saline
Infusion of saline
Saline Solution
Infusion of Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
glucose-dependent insulinotropic peptide
Infusion of GIP
Glucose-Dependent Insulin-Releasing Hormone[3-30]
Infusion of GIP antagonist GIP\[3-30\]
Saline Solution
Infusion of Saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index between 20-27 kg/m\^2
* T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c\<69 mmol/l (\<8,5%)
* T1D duration between 2-20 years
* Stimulated C-peptide ≤ 100 pmol/mL)
* Treatment with a stable basal bolus or insulin pump regimen ≥ 3 months
* Informed consent
Exclusion Criteria
* Liver disease (ALAT and/or ASAT \>2 times normal values) or history of hepatobiliary disorder
* Nephropathy (serum creatinine above normal range and/or albuminuria)
* Allergy or intolerance to ingredients included in the standardized meals
* Prior myocardial infarction or other cardiac events
* Any physical or psychological condition that the investigator fells would interfere with trial participation
* Treatment with any glucose-lowering drugs beside insulin
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steno Diabetes Center Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bjørn Hoe
Medical Doctor, PhD student, Prinicipal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Filip K Knop, MD, PhD
Role: STUDY_DIRECTOR
Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology
Hellerup, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-18002707
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.